2Sawada N, Kondoh K, Moil K. Enhancement of capecitabine effieacy by oxaliplafin in human colorectal and gastric cancer ello-grafts[J]. Oncol Rep, 2007, 18 (4): 775-778.
3Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[ J ]. J Clin Oncol, 2004,22 ( 1 ) : 23-30.
4Stoehlmacher J,Ghaderi V,Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer [ J ]. Anticancer Res, 2001,21 (4B) : 3075 -3079.
5Liu B, Wei J, Zou Z, et al. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population [ J ]. Eur J Hum Genet ,2007,15 ( 10 ) : 1049-1053.
6Parka DJ, Lenza HJ. Determinants of chemosensitivity in gastric cancer [ J ]. Curr Opin Pharmacol,2006,6 (4) :337-344.
7Metzger R,Leichman CG, Danenberg KD, et al. ERCCl mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy [ J]. J Clin Oncol, 1998,16( 1 ) :309-316.
8Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non- small-cell lung cancer[ J]. Ann Oncol, 2004, 15 ( 8 ) : 1194- 1203.
9Olaussen KA, Dunant A, Fouret P, et al . DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[ J]. N Engl J Med,2006,355 (10) :983-991.
10Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer [ J ]. Ann Oncol,2007,18 ( 3 ) :504-509.
